RxDoctor Payments Data

Nazih Isseh, MD

Internal Medicine · Memphis, TNNPI 1912430844

Payments from drug & device makers

$426in general payments, 2019–2025

Across 13 payments — averaging $32.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Daxor Corporation$139
  • Boehringer Ingelheim$111
  • AbbVie$91
  • E.r. Squibb & Sons, L.L.C.$38
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$17
  • Gilead$16
  • plus $14 from 1 others

What the payments were for

  • Food & beverage$426100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$426 in reported general payments places this provider in the 55th percentile of 2,216 internal medicine providers in Tennessee.

See all internal medicine providers in Tennessee

Medicare billing

Part B allowed, 2024
$153,472
Medicare patients
504
Services billed
1,648

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban21$12,756
JardianceEmpagliflozin16$9,387
Albuterol Sulfate HfaAlbuterol Sulfate74$1,676
Naloxone Hcl17$1,014
Midodrine Hcl18$566
Pantoprazole Sodium85$501
Cefdinir52$481
Ondansetron Hcl83$416
Amiodarone Hcl22$343
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav34$257
Doxycycline Monohydrate22$210
Hydralazine Hcl27$206
Fluticasone Propionate23$198
Famotidine15$140
Furosemide46$126

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$14$12,75621 claims
Boehringer IngelheimJardiance$111$9,38716 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 2,216 internal medicine providers in Tennessee.

Other internal medicine in Memphis

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →